Table of Contents Chapter 1 Overview of Viral Conjunctivitis Pipeline Drugs 1.1 Definition of Viral Conjunctivitis Pipeline Drugs in This Report 1.2 Commercial Types of Viral Conjunctivitis Pipeline Drugs 1.2.1 Acute Follicular Conjunctivitis Pipeline Drugs 1.2.2 Subacute Or Chronic Conjunctivitis Pipeline Drugs 1.3 Downstream Application of Viral Conjunctivitis Pipeline Drugs 1.3.1 Hospitals 1.3.2 Clinics 1.3.3 Others 1.4 Development History of Viral Conjunctivitis Pipeline Drugs 1.5 Market Status and Trend of Viral Conjunctivitis Pipeline Drugs 2013-2023 1.5.1 Global Viral Conjunctivitis Pipeline Drugs Market Status and Trend 2013-2023 1.5.2 Regional Viral Conjunctivitis Pipeline Drugs Market Status and Trend 2013-2023 Chapter 2 Global Market Status and Forecast by Regions 2.1 Market Development of Viral Conjunctivitis Pipeline Drugs 2013-2017 2.2 Production Market of Viral Conjunctivitis Pipeline Drugs by Regions 2.2.1 Production Volume of Viral Conjunctivitis Pipeline Drugs by Regions 2.2.2 Production Value of Viral Conjunctivitis Pipeline Drugs by Regions 2.3 Demand Market of Viral Conjunctivitis Pipeline Drugs by Regions 2.4 Production and Demand Status of Viral Conjunctivitis Pipeline Drugs by Regions 2.4.1 Production and Demand Status of Viral Conjunctivitis Pipeline Drugs by Regions 2013-2017 2.4.2 Import and Export Status of Viral Conjunctivitis Pipeline Drugs by Regions 2013-2017 Chapter 3 Global Market Status and Forecast by Types 3.1 Production Volume of Viral Conjunctivitis Pipeline Drugs by Types 3.2 Production Value of Viral Conjunctivitis Pipeline Drugs by Types 3.3 Market Forecast of Viral Conjunctivitis Pipeline Drugs by Types Chapter 4 Global Market Status and Forecast by Downstream Industry 4.1 Demand Volume of Viral Conjunctivitis Pipeline Drugs by Downstream Industry 4.2 Market Forecast of Viral Conjunctivitis Pipeline Drugs by Downstream Industry Chapter 5 Market Driving Factor Analysis of Viral Conjunctivitis Pipeline Drugs 5.1 Global Economy Situation and Trend Overview 5.2 Viral Conjunctivitis Pipeline Drugs Downstream Industry Situation and Trend Overview Chapter 6 Viral Conjunctivitis Pipeline Drugs Market Competition Status by Major Manufacturers 6.1 Production Volume of Viral Conjunctivitis Pipeline Drugs by Major Manufacturers 6.2 Production Value of Viral Conjunctivitis Pipeline Drugs by Major Manufacturers 6.3 Basic Information of Viral Conjunctivitis Pipeline Drugs by Major Manufacturers 6.3.1 Headquarters Location and Established Time of Viral Conjunctivitis Pipeline Drugs Major Manufacturer 6.3.2 Employees and Revenue Level of Viral Conjunctivitis Pipeline Drugs Major Manufacturer 6.4 Market Competition News and Trend 6.4.1 Merger, Consolidation or Acquisition News 6.4.2 Investment or Disinvestment News 6.4.3 New Product Development and Launch Chapter 7 Viral Conjunctivitis Pipeline Drugs Major Manufacturers Introduction and Market Data 7.1 Adenovir Pharma AB 7.1.1 Company profile 7.1.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.1.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Adenovir Pharma AB 7.2 Allergan Plc 7.2.1 Company profile 7.2.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.2.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Allergan Plc 7.3 NanoViricides, Inc 7.3.1 Company profile 7.3.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.3.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of NanoViricides, Inc 7.4 Shire Plc 7.4.1 Company profile 7.4.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.4.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Shire Plc 7.5 NovaBay Pharmaceuticals, Inc 7.5.1 Company profile 7.5.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.5.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of NovaBay Pharmaceuticals, Inc 7.6 Novartis AG 7.6.1 Company profile 7.6.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.6.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Novartis AG 7.7 Panoptes Pharma GESMBH 7.7.1 Company profile 7.7.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.7.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Panoptes Pharma GESMBH 7.8 NicOx SA 7.8.1 Company profile 7.8.2 Representative Viral Conjunctivitis Pipeline Drugs Product 7.8.3 Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of NicOx SA Chapter 8 Upstream and Downstream Market Analysis of Viral Conjunctivitis Pipeline Drugs 8.1 Industry Chain of Viral Conjunctivitis Pipeline Drugs 8.2 Upstream Market and Representative Companies Analysis 8.3 Downstream Market and Representative Companies Analysis Chapter 9 Cost and Gross Margin Analysis of Viral Conjunctivitis Pipeline Drugs 9.1 Cost Structure Analysis of Viral Conjunctivitis Pipeline Drugs 9.2 Raw Materials Cost Analysis of Viral Conjunctivitis Pipeline Drugs 9.3 Labor Cost Analysis of Viral Conjunctivitis Pipeline Drugs 9.4 Manufacturing Expenses Analysis of Viral Conjunctivitis Pipeline Drugs Chapter 10 Marketing Status Analysis of Viral Conjunctivitis Pipeline Drugs 10.1 Marketing Channel 10.1.1 Direct Marketing 10.1.2 Indirect Marketing 10.1.3 Marketing Channel Development Trend 10.2 Market Positioning 10.2.1 Pricing Strategy 10.2.2 Brand Strategy 10.2.3 Target Client 10.3 Distributors/Traders List Chapter 11 Report Conclusion Chapter 12 Research Methodology and Reference 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Reference

List of Tables Table Advantage and Disadvantage of Acute Follicular Conjunctivitis Pipeline Drugs Table Advantage and Disadvantage of Subacute Or Chronic Conjunctivitis Pipeline Drugs Table Production Volume of Viral Conjunctivitis Pipeline Drugs by Regions 2013-2017 Table Production Value of Viral Conjunctivitis Pipeline Drugs by Regions 2013-2017 Table Demand Volume of Viral Conjunctivitis Pipeline Drugs by Regions 2013-2017 Table Production and Demand Status of Viral Conjunctivitis Pipeline Drugs in Region One 2013-2017 Table Production and Demand Status of Viral Conjunctivitis Pipeline Drugs in Region Two 2013-2017 Table Production and Demand Status of Viral Conjunctivitis Pipeline Drugs in Region Three 2013-2017 Table Production and Demand Status of Viral Conjunctivitis Pipeline Drugs in Region Four 2013-2017 Table Import Volume of Viral Conjunctivitis Pipeline Drugs by Regions 2013-2017 Table Export Volume of Viral Conjunctivitis Pipeline Drugs by Regions 2013-2017 Table Production Volume of Viral Conjunctivitis Pipeline Drugs by Types 2013-2017 Table Production Value of Viral Conjunctivitis Pipeline Drugs by Types 2013-2017 Table Production Volume Forecast of Viral Conjunctivitis Pipeline Drugs by Types 2018-2023 Table Production Value Forecast of Viral Conjunctivitis Pipeline Drugs by Types 2018-2023 Table Demand Volume of Viral Conjunctivitis Pipeline Drugs by Downstream Industry 2013-2017 Table Demand Volume Forecast of Viral Conjunctivitis Pipeline Drugs by Downstream Industry 2018-2023 Table Production Volume of Viral Conjunctivitis Pipeline Drugs by Major Manufacturers 2013-2017 Table Production Value of Viral Conjunctivitis Pipeline Drugs by Major Manufacturers 2013-2017 Table Headquarters Location and Established Time of Viral Conjunctivitis Pipeline Drugs Major Manufacturer Table Employees and Revenue Level of Viral Conjunctivitis Pipeline Drugs Major Manufacturer Table Representative Viral Conjunctivitis Pipeline Drugs Product One of Adenovir Pharma AB Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of Adenovir Pharma AB Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Adenovir Pharma AB 2013-2017 Table Representative Viral Conjunctivitis Pipeline Drugs Product One of Allergan Plc Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of Allergan Plc Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Allergan Plc 2013-2017 Table Representative Viral Conjunctivitis Pipeline Drugs Product One of NanoViricides, Inc Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of NanoViricides, Inc Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of NanoViricides, Inc 2013-2017 Table Representative Viral Conjunctivitis Pipeline Drugs Product One of Shire Plc Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of Shire Plc Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Shire Plc 2013-2017 Table Representative Viral Conjunctivitis Pipeline Drugs Product One of NovaBay Pharmaceuticals, Inc Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of NovaBay Pharmaceuticals, Inc Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of NovaBay Pharmaceuticals, Inc 2013-2017 Table Representative Viral Conjunctivitis Pipeline Drugs Product One of Novartis AG Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of Novartis AG Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Novartis AG 2013-2017 Table Representative Viral Conjunctivitis Pipeline Drugs Product One of Panoptes Pharma GESMBH Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of Panoptes Pharma GESMBH Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of Panoptes Pharma GESMBH 2013-2017 Table Representative Viral Conjunctivitis Pipeline Drugs Product One of NicOx SA Table Representative Viral Conjunctivitis Pipeline Drugs Product Two of NicOx SA Table Viral Conjunctivitis Pipeline Drugs Sales, Revenue, Price and Gross Margin of NicOx SA 2013-2017